| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
CB1 inverse agonist 1 targets the cannabinoid CB1 receptor, a G protein-coupled receptor that is the primary mediator of the psychoactive effects of cannabinoids. It acts as an inverse agonist, meaning it not only blocks agonist-induced activation but also reduces constitutive receptor activity. It has an IC50 of 7.5 nM for CB1 and is highly selective over CB2 (IC50 = 4100 nM).
|
|---|---|
| ln Vitro |
In vitro, CB1 inverse agonist 1 potently inhibits CB1 with an IC50 of 7.5 nM. It shows high selectivity over CB2 with an IC50 of 4100 nM. The compound is a specific inverse agonist of the CB1 receptor. Its potent and selective CB1 inverse agonism makes it a valuable tool for studying the endocannabinoid system.
|
| ln Vivo |
Compound 14 (MRL-650) reduces eating in a dose-dependent manner (0.3, 1 or 3 mg/kg) [1]. In Sprague-Dawley rats, C57BL/6 mice, beagle dogs, and rhesus monkeys, the pharmacokinetic properties of CB1 inverse agonist 1 were t1/2 >8, >8, >24, and 22 hours, respectively [1].
In vivo, CB1 inverse agonist 1 is orally active and exhibits anorexigenic effects. As an orally bioavailable CB1 inverse agonist, it can be administered to animal models to study the role of CB1 in appetite regulation, obesity, and metabolic disorders. Its ability to reduce food intake and body weight has been demonstrated in preclinical studies. |
| Enzyme Assay |
In vitro receptor binding assays for CB1 inverse agonist 1 involve measuring its affinity for CB1 and CB2 receptors. Radioligand binding studies using ³H-CP55940 or other cannabinoid ligands are performed on membranes from cells expressing the receptors. The compound is incubated with increasing concentrations, and IC50 values of 7.5 nM for CB1 and 4100 nM for CB2 are determined. Functional assays measure its inverse agonist activity by assessing its ability to reduce constitutive receptor signaling.
|
| Cell Assay |
For in vitro cell-based assays, cells expressing CB1 receptors are cultured and treated with CB1 inverse agonist 1 at various concentrations. Receptor inverse agonism is confirmed by measuring the reduction of constitutive cAMP accumulation or other downstream signaling pathways. Cell viability is assessed by standard assays. The compound's selectivity is confirmed using cells expressing CB2 receptors.
|
| Animal Protocol |
Animal/Disease Models: Rat[1]
Doses: 0.3, 1 or 3 mg/kg Route of Administration: PO Experimental Results: Inhibition of eating in a dose-dependent manner. 3 mg/kg diminished cumulative food intake 2 hrs (hrs (hours)) after dosing. Overnight weight gain was diminished compared with vehicle treatment at all dose levels. In vivo animal studies with CB1 inverse agonist 1 are conducted in models of obesity and metabolic disorders. The compound is administered orally at doses determined from pharmacokinetic studies. Food intake, body weight, and metabolic parameters are monitored. The compound's anorexigenic effects and efficacy in reducing body weight have been demonstrated. Pharmacokinetic parameters are assessed in preclinical species. |
| ADME/Pharmacokinetics |
CB1 inverse agonist 1 (CAS: 852315-00-5) has a molecular weight of 514.79 g/mol and a molecular formula of C25H18Cl3N3O3. Synonyms: MRL-650. Appearance: solid powder. Purity: ≥98%. Solubility: DMSO. Storage: powder at -20°C. The compound is a highly potent and orally active CB1 inverse agonist.
|
| Toxicity/Toxicokinetics |
CB1 inverse agonist 1 is a research compound and is not approved for human therapeutic use. In preclinical studies, it has shown a manageable safety profile. As a CB1 inverse agonist, it may have effects on appetite, mood, and metabolism. The compound's high selectivity for CB1 over CB2 may reduce off-target effects. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
CB1 inverse agonist 1 (MRL-650) is a highly potent, orally active, and specific inverse agonist of the cannabinoid CB1 receptor with an IC50 of 7.5 nM and 4100 nM for CB1 and CB2, respectively. It exhibits anorexigenic effects. It has a molecular weight of 514.79 g/mol and a molecular formula of C25H18Cl3N3O3. It is not FDA-approved and is intended for research use only.
|
| Molecular Formula |
C25H18CL3N3O3
|
|---|---|
| Molecular Weight |
514.79
|
| Exact Mass |
513.041
|
| CAS # |
852315-00-5
|
| PubChem CID |
11386747
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
858
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)C1=C(C2=CC(=C(N=C2N(C1=O)C)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl)NC(=O)C
|
| Synonyms |
CB1 inverse agonist 1; CB1 inverse agonist 1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9425 mL | 9.7127 mL | 19.4254 mL | |
| 5 mM | 0.3885 mL | 1.9425 mL | 3.8851 mL | |
| 10 mM | 0.1943 mL | 0.9713 mL | 1.9425 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
